@60minutes9's Ozempic horror story claims, fact-checked

What did @60minutes9 actually say?

The clip follows Ashley Keenan, who says she spent 10 days in the ICU after taking semaglutide (Ozempic) for four months, was told her "side effects" triggered pancreatitis, nearly died, then went back on the drug after regaining weight, and developed pancreatitis a second time. Her conclusion: "This medication is harmful."

This is a segment from Australia's 60 Minutes, reposted to TikTok with 3.3 million views. It is a single patient's account, framed as a warning about GLP-1 receptor agonists broadly. The framing implies a direct, established causal link between semaglutide and severe pancreatitis. That framing deserves a much closer look.

Does the science back this up?

Pancreatitis appears in semaglutide's prescribing information as a known risk, but the actual population-level data is more complicated than "Ozempic causes pancreatitis."

A large 2023 population-based cohort study by Sodhi et al. published in JAMA Internal Medicine found that GLP-1 receptor agonists were associated with a significantly higher risk of pancreatitis compared to bupropion-naltrexone, with an adjusted hazard ratio of around 9.09 for pancreatitis. That sounds alarming, but absolute rates remain low. The FDA label for semaglutide includes a warning to discontinue use if pancreatitis is suspected and notes that causality has not been definitively established in randomized controlled trials.

The SUSTAIN and STEP trial programs, which enrolled thousands of patients, did not show statistically significant increases in pancreatitis rates versus placebo. Obesity itself is an independent risk factor for pancreatitis, which complicates causality attribution in any individual case.

Ashley's case, two episodes of pancreatitis temporally linked to semaglutide use, is clinically significant and should not be dismissed. But "emerging as a serious concern" overstates the current scientific consensus on population-level risk.

What did they get wrong (or right)?

They got several things right. Pancreatitis is a real, listed risk. Re-challenge (going back on a drug after a serious adverse event) is genuinely concerning, and her doctors monitoring her more closely the second time does not change that. The weight regain after stopping is also well-documented and not a character flaw.

What they got wrong, or at least oversimplified: the video implies pancreatitis is a predictable, common outcome of Ozempic use. It is not. The phrase "perfect storm" is doing a lot of work here. Pancreatitis has multiple causes, including gallstones, alcohol use, hypertriglyceridemia, and prior pancreatic disease. The video does not mention whether Ashley had any pre-existing risk factors, which would be essential context for any honest assessment.

The editorial framing, "terrifying, near-death experience," combined with 3.3 million views, will predictably cause people to stop medically necessary treatment without consulting a clinician. That is a real harm. One patient's serious adverse event, however genuine, is not population-level evidence of broad danger.

What should you actually know?

If you are taking semaglutide or any GLP-1 receptor agonist, pancreatitis is a real risk that warrants awareness. Symptoms include persistent, severe abdominal pain that may radiate to the back, nausea, and vomiting. If you experience these, stop the medication and go to an emergency department. Do not wait.

What you should not do is stop your medication because of a viral TikTok without speaking to your prescriber. For people managing type 2 diabetes or obesity-related cardiovascular risk, the benefit-to-risk calculation for GLP-1 drugs is supported by substantial clinical trial data, including the SUSTAIN-6 trial (Marso et al., 2016, NEJM) showing cardiovascular mortality reduction in high-risk patients.

If you have a personal or family history of pancreatitis, pancreatic cancer, or certain thyroid conditions, your prescriber should already be factoring that into whether this class of medication is appropriate for you. If they are not, that is worth a direct conversation.

• Pancreatitis is listed as a warning in semaglutide's FDA prescribing information.
• Recurrence of pancreatitis after re-challenge with the same drug is a serious signal that should end use of that drug permanently, not a monitoring problem.
• Obesity independently raises pancreatitis risk, making causality in individual cases genuinely hard to establish.
• Stopping a GLP-1 drug abruptly after a serious adverse event is appropriate. Stopping without cause because of viral content is a different, potentially harmful decision.